A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia

Investigator: Tetsuo Ashizawa, MD

Study Coordinator: Titilayo Olubajo

Status: Enrolling

ClinicalTrials.gov Number: NCT02960893

Phone: 713.363.9803

Protocol Number: Pro00015303


The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
More to Explore